Initiator Pharma (INIT) Q1 2025 earnings summary

Executive summary

• Advanced clinical programs in sexual health and pain, with focus on pudafensine and IP2018, showing strong efficacy and safety in recent trials.

• Expansion of leadership with Dr. Göran Ando proposed for Board and appointed Senior Advisor.

• Continued business development, clinical planning, and pipeline growth, targeting unmet needs in male and female sexual health and pain.

Financial highlights

• No revenue generated in Q1 2025; operating loss of TDKK 2,653, improved from TDKK 3,577 in Q1 2024.

• Net loss for Q1 2025 was TDKK 2,653 (Q1 2024: TDKK 4,123); EPS at DKK -0.05 (Q1 2024: -0.08).

• Cash and cash equivalents at March 31, 2025: TDKK 10,782, down from TDKK 13,371 at year-end 2024.

• Equity as of March 31, 2025: TDKK 12,129; equity ratio 92%.

• Cash flow from operating activities in Q1 2025: TDKK -2,589, a significant improvement from TDKK -6,802 in Q1 2024.

Outlook and guidance

• Priorities include launching next phase of pudafensine clinical development in ED, advancing FSD and pain programs, and exploring strategic collaborations.

• Management and Board believe the company is well positioned to secure necessary financing for continued operations.